Based on the body of evidence, it is predicted that CAR T cells manufactured with interleukin-15 will exhibit a significantly increased release of pro-inflammatory cytokines, such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), compared to CAR T cells manufactured without it.